A Phase I/II Trial of EMB-02, a Bi-specific Antibody Against PD-1 and LAG-3, in Patients with Advanced Solid Tumors
This is a Phase I/II trial with at least 17 patients in the dose escalation phase and 26-45 patients in the Phase II portion of the trial. In the Phase I portion of the trial, patients will receive EMB-02 at doses escalating from 6 to 900 mg IV once weekly. Following the evaluation of initial PK data, the dosing interval might be adjusted (e.g., to every 2 weeks or longer) should there be drug accumulation upon repeated dosing. Any change to dose interval due to safety concerns will involve data review by the Safety Review Committee and a protocol amendment. One treatment cycle is defined as 28 days. The doselimiting toxicity observation period is defined as 28 days.
MoreAdult
Patients with histologically or cytologically confirmed locally advanced/metastatic solid tumors only including melanoma (excluding uveal melanoma), cutaneous squamous cell carcinoma (CSCC), non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), mesothelioma, head and neck squamous cell carcinoma (HNSCC), nasopharyngeal cancer (NPC), hepatocellular carcinoma (HCC), gastric cancer(GC) and small cell lung cancer (SCLC), Standard therapies do not exist, are no longer effective, or are not tolerable or accessible to the patient Measurable or evaluable disease per RECIST v1.1
Treatment
Memorial Hospital Central
Memorial Hospital North
Robert Hoyer
Protocol Number: 20-2545
More information available at ClinicalTrials.gov: NCT04618393
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers